奥马珠单抗治疗慢性自发性荨麻疹期间心理状态及炎症生物标志物的改善
Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria.
作者信息
Diluvio Laura, Piccolo Arianna, Marasco Francesco, Vollono Laura, Lanna Caterina, Chiaramonte Barbara, Niolu Cinzia, Campione Elena, Bianchi Luca
机构信息
Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
Psychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
出版信息
Future Sci OA. 2020 Aug 10;6(9):FSO618. doi: 10.2144/fsoa-2020-0087.
BACKGROUND
Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab.
MATERIALS & METHODS: A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months.
RESULTS
The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers.
CONCLUSION
Omalizumab allowed an improvement of urticaria and mental comorbidities.
背景
抑郁和焦虑是慢性自发性荨麻疹（CSU）最常见的精神共病。奥马珠单抗是一种被批准用于治疗CSU的单克隆抗体。我们评估了CSU患者在接受奥马珠单抗治疗前后焦虑和抑郁的患病率。
材料与方法
共有30名患者纳入本研究：15名受CSU影响并接受奥马珠单抗治疗的患者，另外15名健康受试者未接受任何全身治疗。所有患者在基线时和6个月后使用医院焦虑抑郁量表、CRP和红细胞沉降率进行评估。
结果
治疗6个月后，奥马珠单抗组所有评分和生物标志物均下降。
结论
奥马珠单抗可改善荨麻疹和精神共病。
Zotero 插件